Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 7, 2015, Pages 1689-1702

  Leung, Ting Fan ^a   Liu, Anthony Pak Yin ^b   Lim, Fong Seng ^c   Thollot, Franck ^d   Oh, Helen May Lin ^e   Lee, Bee Wah ^c   Rombo, Lars ^f   Tan, Ngiap Chuan ^g   Rouzier, Roman ^h   Friel, Damien ⁱ   de Muynck, Benoit ⁱ   de Simoni, Stéphanie ⁱ   Suryakiran, Pemmaraju ^j   Hezareh, Marjan ⁱ   Folschweiller, Nicolas ⁱ   Thomas, Florence ⁱ   Struyf, Frank ⁱ  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d AFPA Association Française de Pédiatrie Ambulatoire   (France)

^e CHANGI GENERAL HOSPITAL   (Singapore)

^f KAROLINSKA INSTITUTE   (Sweden)

^g SINGHEALTH POLYCLINICS   (Singapore)

^h INSTITUT CURIE   (France)

ⁱ GSK   (Belgium)

^j GlaxoSmithKline Pharmaceuticals Ltd   (India)

more..

Author keywords

Administration schedule; Female adolescents; Human papillomavirus (HPV) vaccines; Immunogenicity; Safety

Indexed keywords

HPV 16 18 AS04 ADJUVANTED VACCINE; HPV 6 11 16 18 VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; IMMUNOLOGICAL ADJUVANT; VACCINE;

ADOLESCENT; ALOPECIA AREATA; ANTIBODY RESPONSE; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELIAC DISEASE; CELLULAR IMMUNITY; CHILD; CLINICAL TRIAL; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA NODOSUM; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; JUVENILE RHEUMATOID ARTHRITIS; MYALGIA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; T LYMPHOCYTE; ULCERATIVE COLITIS; ALPHAPAPILLOMAVIRUS; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTIONS; TIME FACTOR;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ALPHAPAPILLOMAVIRUS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TIME FACTORS; VACCINE POTENCY;

EID: 84944459720     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1050570     Document Type: Article

References (50)

1. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. Comparison of the immunogenicity and safety of CervarixTM and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705- 19; PMID:19684472; http://dx. doi. org/10. 4161/ hv. 5. 10. 9518
2. de Sanjosé S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56; PMID:20952254; http://dx. doi. org/ 10. 1016/S1470-2045(10)70230-8
3. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128:927-35; PMID:20473886; http://dx. doi. org/10. 1002/ijc. 25396
4. Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M, Cosano R, Muñoz J, Bosch FX, de Sanjosé S. ICO information centre on HPV and cancer (HPV Information Centre). Human papillomavirus and related diseases in World. Summary Report 2014-08-22. Available from: http://www. hpvcentre. net/statistics/ reports/XWX. pdf. Accessed 7 April 2015.
5. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-71; PMID:17531764; http://dx. doi. org/10. 1016/j. jadohealth. 2007. 02. 015
6. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-45; PMID:17079588; http://dx. doi. org/ 10. 1542/peds. 2006-0461
7. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757- 65; PMID:15541448; http://dx. doi. org/10. 1016/ S0140-6736(04)17398-4
8. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55; PMID:16631880; http://dx. doi. org/10. 1016/S0140-6736(06)68439-0
9. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx. doi. org/ 10. 1016/S0140-6736(09)61248-4
10. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, et al. Overall efficacy of HPV-16/ 18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99; PMID:22075171; http://dx. doi. org/10. 1016/S1470-2045(11)70286-8
11. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10; PMID:22075170; http://dx. doi. org/10. 1016/S1470-2045(11)70287-X
12. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007; 196:1438-46; PMID:18008221; http://dx. doi. org/10. 1086/522864
13. Ault KA, FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369:1861-8; PMID:17544766; http://dx. doi. org/ 10. 1016/S0140-6736(07)60852-6
14. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of theHPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study. Hum Vaccin 2011; 7:1374-86; PMID:22048171; http://dx. doi. org/ 10. 4161/hv. 7. 12. 18322
15. Puthanakit T, Huang L, Tang R, Schwarz T, Esposito S, Frenette L, McNeil S, Rheault P, Horn M, Klar M, et al. Non-inferiority of HPV-16/18 AS04-adjuvanted vaccine administered as 2-dose schedules in girls (9- 14 years) versus 3 doses in women (15-25 years): a randomised trial. Abstract presented at ESPID 2014. May 6-10, 2014. Dublin, Ireland. Available at: http:// cmoffice. kenes. com/cddemo/data/HtmlApp/main. html#. Accessed 7 April 2015
16. Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. Hum Vaccin Immunother 2014; 10:1155-65; PMID:24576907; http://dx. doi. org/10. 4161/hv. 28022
17. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802; PMID:23632723; http://dx. doi. org/10. 1001/jama. 2013. 1625
18. European Medicines Agency. European public assessment report. Cervarix: human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed). EMEA/H/C/ 000721. Available from: http://www. ema. europa. eu/docs/ en_GB/document_library/EPAR_-_Summary_for_ the_public/human/000721/WC500024634. pdf. Accessed 7 April 2015.
19. European Medicines Agency. European public assessment report. Gardasil: human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed). EMEA/ H/C/000703. Available from: http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Summar y_for_the_public/human/000703/WC500021146. pdf. Accessed 7 April 2015.
20. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsagué X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double- blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx. doi. org/ 10. 1016/S0140-6736(07)60946-5
21. Harper DM, Verdenius I, Ratnaraj F, Arey AM, Rosemergey B, Malnar GJ, Wall J. Quantifying clinical HPV4 dose inefficiencies in a safety net population. PLoS One 2013; 8:e77961; PMID:24223131; http:// dx. doi. org/10. 1371/journal. pone. 0077961
22. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012; 30 Suppl 5:F139-48; PMID:23199957; http://dx. doi. org/ 10. 1016/j. vaccine. 2012. 05. 039
23. Hopkins TG, Wood N. Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine 2013; 31:1673-9; PMID:23375978; http://dx. doi. org/10. 1016/j. vaccine. 2013. 01. 028
24. Harper DM, Verdenius I, Harris GD, Barnett AL, Rosemergey BE, Arey AM, Wall J, Malnar GJ. The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series. Prev Med 2014; 61:20-5; PMID:24440159; http://dx. doi. org/10. 1016/j. ypmed. 2014. 01. 007
25. Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, BlatterMM, Lalezari J, DavidMP, Lin L, Struyf F, et al. Comparison of long-termimmunogenicity and safety of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial. HumVaccin Immunother 2014;10:3435-45; PMID:25483701; http://dx. doi. org/ 10. 4161/hv. 36121
26. Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S. A randomized, observer-blinded immunogenicity trial of Cervarix® and Gardasil® human papillomavirus vaccines in 12-15 year old girls. PLoS One 2013; 8: e61825; PMID:23650505; http://dx. doi. org/10. 1371/ journal. pone. 0061825
27. Toft L, Storgaard M, Muller M, Sehr P, Bonde J, Tolstrup M, Østergaard L, Søgaard OS. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 2014; 209:1165-73; PMID:24273179; http://dx. doi. org/10. 1093/infdis/jit657
28. Barzon L, Squarzon L, Masiero S, Pacenti M, Marcati G, Mantelli B, Gabrielli L, Lazzarotto T, Caputo A, Palu G. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Vaccine 2014; 32:5357-62; PMID:25045814; http://dx. doi. org/ 10. 1016/j. vaccine. 2014. 07. 014
29. Castellsagué X, Naud P, Chow SN, Wheeler CM, GermarMJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmeron J, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J InfectDis 2014; 210:517-34; PMID:24610876; http://dx. doi. org/ 10. 1093/infdis/jiu139
30. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and ¡18 infections. J Natl Cancer Inst 2010; 102:1653-62; PMID:20944077; http://dx. doi. org/10. 1093/jnci/djq384
31. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298:2199- 202; PMID:12481138; http://dx. doi. org/10. 1126/ science. 1076071
32. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003; 171:4969-73; PMID:14607890; http://dx. doi. org/ 10. 4049/jimmunol. 171. 10. 4969
33. Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 2003; 21 Suppl 2:S35-7; PMID:12763680; http://dx. doi. org/10. 1016/S0264- 410X(03)00198-1
34. Angelo MG, David MP, Zima J, Baril L, Dubin G, Arellano F, Struyf F. Pooled analysis of large and longterm safety data from the human papillomavirus-16/ 18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 2014; 23:466-79; PMID:24644063; http://dx. doi. org/10. 1002/pds. 3554
35. Angelo MG, Zima J, Tavares Da Silva F, Baril L, Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 2014; 23:456-65; PMID:24644078; http://dx. doi. org/10. 1002/pds. 3593
36. Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 2010; 29:95-101; PMID:19952863; http://dx. doi. org/10. 1097/INF. 0b013e3181b77906
37. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39; PMID:17931153; http://dx. doi. org/ 10. 1586/14760584. 6. 5. 723
38. Garçon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 2011; 25:217-26; PMID:21815697; http://dx. doi. org/10. 2165/11591760- 000000000-00000
39. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937-49; PMID:16828940; http://dx. doi. org/10. 1016/j. vaccine. 2006. 06. 005
40. Caulfield MJ, Shi L, Wang S, Wang B, Tobery TW, Mach H, Ahl PL, Cannon JL, Cook JC, Heinrichs JH, et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum Vaccin 2007; 3:139-45; PMID:17581283; http://dx. doi. org/10. 4161/hv. 3. 4. 4309
41. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04- adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425-34; PMID:18948732; http://dx. doi. org/10. 4161/hv. 4. 6. 6912
42. Robbins HA, Kemp TJ, Porras C, Rodriguez AC, Schiffman M, Wacholder S, Gonzalez P, Schiller J, Lowy D, Poncelet S, et al. Comparison of antibody responses to human papillomavirus vaccination as measured by three assays. Front Oncol 2014; 3:328; PMID:24455487; http://dx. doi. org/10. 3389/fonc. 2013. 00328
43. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger KS, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, highthroughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321:205-16; PMID:15051381; http://dx. doi. org/ 10. 1016/j. virol. 2003. 12. 027
44. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286:111-22; PMID:15087226; http://dx. doi. org/10. 1016/j. jim. 2003. 12. 015
45. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/ 18 vaccine: Follow-up from Months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011; 7:1343-58; PMID:22048173; http:// dx. doi. org/10. 4161/hv. 7. 12. 18281
46. Moris P, van der Most R, Leroux-Roels I, Clement F, Drame M, Hanon E, Leroux-Roels GG, Van Mechelen M. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54; PMID:21174144; http://dx. doi. org/10. 1007/s10875- 010-9490-6
47. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, Chiu YL, McElrath MJ, De Rosa SC. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007; 323:39-54; PMID:17451739; http://dx. doi. org/ 10. 1016/j. jim. 2007. 03. 002
48. Chattopadhyay PK, Yu J, Roederer M. Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression. Nat Protoc 2006; 1:1-6; PMID:17406204; http://dx. doi. org/10. 1038/nprot. 2006. 1
49. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M, Scheffold A, Thiel A. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 2005; 11:1118-24; PMID:16186818; http://dx. doi. org/10. 1038/nm1292
50. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Statistical Principles for Clinical Trials (E9). 5 February 1998. Available from: http://www. ich. org/fil eadmin/Public_Web_Site/ICH_Products/Guidelines/ Efficacy/E9/Step4/E9_Guideline. pdf. Accessed 7 April 2015.